Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;25(2):e302-e310.
doi: 10.1634/theoncologist.2019-0407. Epub 2019 Oct 14.

Lenvatinib in Management of Solid Tumors

Zhonglin Hao  1   2 , Peng Wang  1   2
Affiliations
Review

Lenvatinib in Management of Solid Tumors

Zhonglin Hao et al. Oncologist. 2020 Feb.

Abstract

Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in cancer therapy. Displaying activity in multiple solid tumors, it has been approved in differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma as single agent or in combination. In addition, lenvatinib has shown promise in several other tumor types including medullary, anaplastic thyroid, adenoid cystic, and endometrial cancer. Exploring synergy between angiogenic and immune checkpoint inhibitors, the lenvatinib/pembrolizumab combination is poised to become the next pair of active drugs in endometrial, lung, and gastrointestinal malignancies. Despite robust activity, the drug can be difficult to tolerate. Optimization of dose and biomarkers for prediction of efficacy and toxicities will be of great help. IMPLICATIONS FOR PRACTICE: Readers will be presented with an update on U.S. Food and Drug Administration approval of lenvatinib and suggestions for off-label use in thyroid cancer and adenoid cystic carcinomas. They will become familiarized with the common side effects, frequency, and predicators of response. In addition, they will learn that different strengths of lenvatinib are prescribed and why. Finally, readers are pointed to the latest efforts to combine lenvatinib and pembrolizumab, as well as to unresolved issues such as long-term side effects/toxicities of this drug.

Keywords: Angiogenesis inhibitor; Cancer; Lenvatinib; Pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

References

    1. Cohen P. The regulation of protein function by multisite phosphorylation—A 25 year update. Trends Biochem Sci 2000;25:596–601. - PubMed
    1. Tarrant MK, Cole PA. The chemical biology of protein phosphorylation. Annu Rev Biochem 2009;78:797–825. - PMC - PubMed
    1. Mansour SJ, Matten WT, Hermann AS et al. Transformation of mammalian cells by constitutively active map kinase kinase. Science 1994;265:966–970. - PubMed
    1. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007;17:60–65. - PubMed
    1. Fedorov O, Muller S, Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010;6:166–169. - PubMed

MeSH terms